Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
A normal echocardiogram doesn't always mean a healthy heart. Persistent symptoms like breathlessness and fatigue can indicate ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...
Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
Heart failure (HF) and atrial fibrillation (AF) are a bad combination, such that AF can exacerbate HF symptoms, worsen left ventricular function, and create multiple adverse consequences despite ...
MADRID, Spain—Two randomized, controlled trials testing beta-blockers in post-MI patients without heart failure or impaired left ventricular ejection fraction added a bit of confusion to a field ...
Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...
The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced. The nonsteroidal mineralocorticoid receptor antagonist (MRA) is the first of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback